Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in RA with Inadequate Response to Methotrexate
NCT02969044Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing PF-06651600 with Placebo (2 arms). Primary endpoint: Change From Baseline in Simple Disease Activity Index at 8 weeks. Started Dec 2016; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02969044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02969044.